Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, Wheatley-Price P, Milano C, Clemons M.

Curr Oncol. 2012 Dec;19(6):e414-21. doi: 10.3747/co.19.1074.

2.

Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M.

J Support Oncol. 2013 Mar;11(1):14-21.

PMID:
22763232
3.

Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.

Shih V, Wan HS, Chan A.

Ann Pharmacother. 2009 Mar;43(3):444-52. doi: 10.1345/aph.1L437. Epub 2009 Feb 3.

PMID:
19193584
4.
5.

Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.

Liau CT, Chu NM, Liu HE, Deuson R, Lien J, Chen JS.

Support Care Cancer. 2005 May;13(5):277-86. Epub 2005 Mar 16.

PMID:
15770489
6.

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

Navari RM.

J Support Oncol. 2003 Jul-Aug;1(2):89-103. Review.

PMID:
15352652
7.

Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists.

Majem M, Moreno ME, Calvo N, Feliu A, Pérez J, Mangues MA, Barnadas A.

Support Care Cancer. 2011 Dec;19(12):1983-90. doi: 10.1007/s00520-010-1042-3. Epub 2010 Nov 18.

PMID:
21086141
8.

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.

Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G.

Cancer. 2004 May 15;100(10):2261-8.

9.

Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.

Abbrederis K, Lorenzen S, Rothling N, Ihbe-Heffinger A, Schuster T, Peschel C, Lordick F.

Onkologie. 2009 Feb;32(1-2):30-4. doi: 10.1159/000183735. Epub 2009 Jan 20.

PMID:
19209016
10.

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.

Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H.

Support Care Cancer. 2007 May;15(5):497-503. Epub 2006 Nov 14.

PMID:
17103197
11.

Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).

Hesketh PJ, Morrow G, Komorowski AW, Ahmed R, Cox D.

Support Care Cancer. 2012 Oct;20(10):2633-7. doi: 10.1007/s00520-012-1527-3. Epub 2012 Jun 24.

PMID:
22733373
12.
13.

Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.

Feinberg B, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D.

Support Care Cancer. 2012 Mar;20(3):615-23. doi: 10.1007/s00520-011-1140-x. Epub 2011 Mar 29.

PMID:
21761096
14.
15.

Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study.

López-Jiménez J, Martín-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, del Campo R, Fernández C, Calbacho M, García-Belmonte D, Fernández G.

Haematologica. 2006 Jan;91(1):84-91.

16.

Nausea and vomiting perspectives among children receiving moderate to highly emetogenic chemotherapy treatment.

Rodgers C, Kollar D, Taylor O, Bryant R, Crockett K, Gregurich MA, Hockenberry M.

Cancer Nurs. 2012 May-Jun;35(3):203-10. doi: 10.1097/NCC.0b013e3182281493.

PMID:
21915041
17.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
18.

Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47. Epub 2011 Jun 28.

PMID:
21711119
19.

Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed.

Erazo Valle A, Wisniewski T, Figueroa Vadillo JI, Burke TA, Martinez Corona R.

Curr Med Res Opin. 2006 Dec;22(12):2403-10.

PMID:
17257454

Supplemental Content

Support Center